These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31206934)

  • 1. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
    Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
    Shima H; Tsurita G; Wada S; Hirohashi Y; Yasui H; Hayashi H; Miyakoshi T; Watanabe K; Murai A; Asanuma H; Tokita S; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nakae Y; Sugita O; Ito YM; Ota Y; Kimura Y; Kutomi G; Hirata K; Mizuguchi T; Imai K; Takemasa I; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2378-2385. PubMed ID: 31218770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
    Shima H; Kutomi G; Satomi F; Imamura M; Kimura Y; Mizuguchi T; Watanabe K; Takahashi A; Murai A; Tsukahara T; Kanaseki T; Hirohashi Y; Iwayama Y; Tsuruma T; Kameshima H; Sato N; Torigoe T; Takemasa I
    Cancer Immunol Immunother; 2018 Oct; 67(10):1603-1609. PubMed ID: 30069687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes.
    Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K
    Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
    Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
    Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
    Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
    Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.
    Watanabe K; Tsukahara T; Toji S; Saitoh S; Hirohashi Y; Nakatsugawa M; Kubo T; Kanaseki T; Kameshima H; Terui T; Sato N; Torigoe T
    Cancer Sci; 2019 Jan; 110(1):40-51. PubMed ID: 30375705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.
    Circosta P; Vitaggio K; Elia AR; Todorovic M; Sangiolo D; Carnevale-Schianca F; Vallario A; Geuna M; Aglietta M; Cignetti A
    Immunotherapy; 2018 Jul; 10(9):753-767. PubMed ID: 30008257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
    Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
    J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
    Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
    Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.